Long term primary human tumor cell cultures and mixed autologous tumor-lymphocyte cultures for adoptive specific antitumoral immunotherapy

Anticancer Research

Volumn 18, Issue 1 A, 1998, Pages 41-44

  Rizzo, Sebastiano ^a   Silvotti, Maria G ^a   Martano, Francesca ^a   Santamaria, Amalia Bianchi ^a   Pontiggia, Paolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anticancer therapy; Autologous vaccine; Immunotherapy; Mixed cultures; Tumor cell culture

Indexed keywords

CANCER VACCINE; CYTOKINE; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BONE MARROW CANCER; BREAST TUMOR; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE CULTURE; LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR CELL CULTURE;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031948403     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Livingston P, Bystryn JC, Ferrone S: "Preface". In: Procedings of the Conference of the New York Academy of Sciences on Specific Immunotherapy of Cancer with Vaccines (Bystryn JC, Ferrone S, Livingston P, eds). New York, Annals NYAS, 1993, vol 690, p. XI.
2. MacLean GD and Longenecker BM: New possibilities for cancer therapy with advances in cancer immunology. Can J Oncol 4: 249-254, 1994.
3. Chang AE, Geiger JD, Sondak VK, Shu S: Adoptive cellular therapy of malignancy. Arch Surg 128: 1281 -1290,1993.
4. Alonso K: Human-human monoclonal antibody directed against tumor surface antigen in the treatment of human malignancy. Am J Clin Oncol 14: 463-471, 1991.
5. Hersey P: Melanoma Vaccines. Current Status and Future Prospects. Drugs 47: 373-382, 1994.
6. Rosenberg SA. Gene therapy for cancer. JAMA 268: 2416-2419, 1992.
7. Gold JE, Osband ME, Krane RJ: Adoptive cellular therapy of urological neoplastic disease. Cancer Treatment Revues 20: 173-190, 1994.
8. Hersey P. Cellular therapy. Curr Opin Oncol 5: 1049-1054, 1993.
9. Hladik F, Kolbe K, Irschick EU, et al: IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-P). Ann Hematol 67: 67-74, 1993.
10. Medenica R, Alonso K. Production of Patient Antitumor Specific Interferon (Tentatively named IFN-Pi). Blood 70s: 112, 1987.
11. Logothetou-Rella, H, Stamboulieh-Abazis, D, Tentas, K. Common characteristic of primary cell cultures originated from metastatic lung carcinomas. J Exp Clin Cancer Res 11: 285-301, 1992.
12. Old LJ: Cancer immunology: the search for specifity. Cancer Res 41: 361-375, 1981.
13. Parkins CS and Steel GG: Growth and radiosensitivity testing of human tumor cells using the adhesive tumor cell culture system. Br J Cancer 62: 935-941, 1990.
14. Vanky F, Klein E: Specifity of antitumor cytotoxicity exerted by fresh activated and propagated human T-lymphocytes. Int J Cancer 29: 547-551, 1982.
15. Vose BM, White W: Tumor reactive lymphocytes stimulated in mixed lymphocyte and tumor cultures. Cancer Immunol Immunother 15: 227-236, 1983
16. de Vries JE, Spitz M: Cloned human -cytotoxic T-lymphocytes (CTL) lines reactive with autologous melanoma cells. J Immunol 132: 510-516, 1984.
17. Osband ME, Krane RJ: Autolymphocyte therapy: previous experience and future prospects. Pathol Immunopathol Res 7: 483-493, 1988.
18. Vose BM, Bonnard GB: Specific cytotoxiciry against autologous tumor and proliferative responses of human lymphocytes grown in interleukin 2. Int J Cancer 29: 33-39, 1982.
19. Sensi M, Farina C, Maccalli C et al: Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest 99: 710-717, 1997.
20. Arienti F, Sule Suso J, Belli F et al: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogenic melanoma cells. Human Gene Ther 7: 1955-1963, 1996.
21. Klehr NW. (personal communication) 1990.